| SELLING STOCKHOLDERS | ||||||||
Filed Pursuant to Rule 424(b)(3)
Registration Statement No. 333-81432
Prospectus Supplement No. 1
to
Prospectus Dated February 4, 2002
LA JOLLA PHARMACEUTICAL COMPANY
Common Stock
The following information supplements, and must be read in connection with, the information contained in the Prospectus, dated February 4, 2002 (the “Prospectus”), of La Jolla Pharmaceutical Company, a Delaware corporation. This Prospectus Supplement must be delivered with a copy of the Prospectus. All capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Prospectus.
The following information replaces in its entirety the information provided in the Prospectus under the caption “Selling Stockholders.”
SELLING STOCKHOLDERS
In a series of private transactions completed on January 17, 2002, we issued a total of 7,000,000 shares of our common stock to the stockholders listed below. The selling stockholders may from time to time offer and sell pursuant to this prospectus any or all of 7,000,000 shares of our common stock. The following table describes, as of May 7, 2002, the number of shares of our common stock that each selling stockholder beneficially owns and the number of shares registered hereunder. The term “selling stockholders” includes the holders listed below and their transferees, pledgees, donees or other successors. We have prepared this table based upon information furnished to us by or on behalf of the selling stockholders.
The selling stockholders confirmed at the time they acquired the shares listed below that they acquired the shares for investment purposes only and not with a view toward their resale, and acknowledged the existence of restrictions on resale that apply to these shares. This offering relates only to the sale of the 7,000,000 shares of common stock held or to be held by the selling stockholders named in the following table. Since the date on which they provided us with the information below, the selling stockholders may have sold, transferred or otherwise disposed of some or all of their shares of our common stock in transactions exempt from the registration requirements of the Securities Act.
| Shares of Common Stock | Shares of Common Stock | |||||||||||||||||||
| Owned Prior to Offering | Owned After Offering | |||||||||||||||||||
| Percent of | Shares to be | Number of | Percent of | |||||||||||||||||
| Name of Selling Stockholder | Number of Shares | Class(%)(1) | Sold(2) | Shares(2) | Class(%)(2) | |||||||||||||||
SAFECO Growth Opportunities Fund — A series of SAFECO Common Stock Trust |
1,216,000 | 2.9 | 1,216,000 | — | — | |||||||||||||||
Deka-Team-Biotech (3) |
1,019,009 | 2.4 | 484,450 | 534,559 | 1.3 | |||||||||||||||
Deerfield Partners, L.P. |
746,936 | 1.8 | 139,750 | 607,186 | 1.4 | |||||||||||||||
Deerfield International Limited |
589,264 | 1.4 | 110,250 | 479,014 | 1.1 | |||||||||||||||
Growth Opportunities Fund — A series of SAFECO Resource Series Trust |
584,000 | 1.4 | 584,000 | — | — | |||||||||||||||
Brookside Capital Partners Fund, L.P. |
500,000 | 1.2 | 500,000 | — | — | |||||||||||||||
SEI Institutional Managed Trust |
344,800 | * | 318,500 | 26,300 | * | |||||||||||||||
Compound Capital Growth Partners, Ltd. |
320,294 | * | 320,294 | — | — | |||||||||||||||
| Shares of Common Stock | Shares of Common Stock | |||||||||||||||||||
| Owned Prior to Offering | Owned After Offering | |||||||||||||||||||
| Percent of | Shares to be | Number of | Percent of | |||||||||||||||||
| Name of Selling Stockholder | Number of Shares | Class(%)(1) | Sold(2) | Shares(2) | Class(%)(2) | |||||||||||||||
EGS Private Healthcare Partnership II, L.P. |
303,085 | * | 303,085 | — | — | |||||||||||||||
Special Situations Fund III, L.P. |
285,000 | * | 285,000 | — | — | |||||||||||||||
SEI Institutional Investments Trust |
257,200 | * | 237,200 | 20,000 | * | |||||||||||||||
Zeke, LP |
225,000 | * | 225,000 | — | — | |||||||||||||||
RS Smaller Company Growth Fund |
210,600 | * | 75,000 | 135,600 | * | |||||||||||||||
SF Capital Partners, LTD |
200,000 | * | 200,000 | — | — | |||||||||||||||
JP Morgan U.S. Small Company Fund |
170,750 | * | 28,350 | 142,400 | * | |||||||||||||||
Compound Capital Growth Partners II, LP |
153,900 | * | 153,900 | — | — | |||||||||||||||
Utah Retirement Systems |
141,000 | * | 130,100 | 10,900 | * | |||||||||||||||
Special Situations Private Equity Fund, L.P. |
125,000 | * | 125,000 | — | — | |||||||||||||||
Anvers Healthcare Investors, LP |
124,000 | * | 63,000 | 61,000 | * | |||||||||||||||
Pierpont Small Company Opportunities Fund |
121,932 | * | 20,600 | 101,332 | * | |||||||||||||||
CCGrowth Global Life Sciences Ltd. |
122,573 | * | 106,614 | 15,959 | * | |||||||||||||||
UBS Global Equity Arbitrage Master Limited |
100,000 | * | 100,000 | — | — | |||||||||||||||
O’Connor PIPES Corporate Strategies Ltd. |
100,000 | * | 100,000 | — | — | |||||||||||||||
Special Situations Cayman Fund, L.P. |
90,000 | * | 90,000 | — | — | |||||||||||||||
JPMCB U.S. Small Company Equity I Growth |
84,200 | * | 13,175 | 71,025 | * | |||||||||||||||
G. Nicholas Farwell(4) |
75,000 | * | 75,000 | — | — | |||||||||||||||
CCGrowth Global Life Sciences I, LP |
58,097 | * | 58,097 | — | * | |||||||||||||||
RS Orphan Fund, L.P. |
70,000 | * | 70,000 | — | — | |||||||||||||||
Compound Capital Growth Partners III, LP |
68,073 | * | 68,073 | — | — | |||||||||||||||
Ivory Opportunity Fund, LP |
67,500 | * | 67,500 | — | — | |||||||||||||||
JPM Tax Aware Small Company Opportunities
Fund |
67,361 | * | 14,200 | 53,161 | * | |||||||||||||||
Daughter’s of Charity Fund P |
61,900 | * | 57,100 | 4,800 | * | |||||||||||||||
Undiscovered Managers Small Cap Growth Fund |
61,100 | * | 56,200 | 4,900 | * | |||||||||||||||
Compound Capital Growth Partnership, LP |
50,799 | * | 50,799 | — | — | |||||||||||||||
AIG DKR Soundshore Holdings Ltd. |
50,000 | * | 50,000 | — | — | |||||||||||||||
EGS Private Healthcare Investors II, L.P. |
47,800 | * | 47,800 | — | — | |||||||||||||||
EGS Private Healthcare Canadian Partners,
L.P. |
45,607 | * | 45,607 | — | — | |||||||||||||||
Vision Small Cap Stock Fund |
39,100 | * | 36,100 | 3,000 | * | |||||||||||||||
Alfred I. Dupont Testamentary Trust |
33,300 | * | 30,700 | 2,600 | * | |||||||||||||||
Ivory Opportunity Fund, Ltd. |
32,500 | * | 32,500 | — | — | |||||||||||||||
Les Schwab P/S Retirement Trust |
30,300 | * | 28,000 | 2,300 | * | |||||||||||||||
RS Orphan Offshore Fund, L.P. |
30,000 | * | 30,000 | — | — | |||||||||||||||
CCGrowth Global Life Sciences II, LP |
35,741 | * | 30,954 | 4,787 | * | |||||||||||||||
East Bay Municipal Utility District |
25,900 | * | 23,900 | 2,000 | * | |||||||||||||||
Met. Inv. Tr Small Cap Stock — SSB |
25,425 | * | 3,925 | 21,500 | * | |||||||||||||||
The Paisley Fund, LP |
25,000 | * | 25,000 | — | — | |||||||||||||||
JP Morgan Global Healthcare Fund(3) |
22,709 | * | 3,850 | 18,859 | * | |||||||||||||||
Anvers Healthcare Investors International,
Ltd. |
22,700 | * | 12,000 | 10,700 | * | |||||||||||||||
Philips Pensionenfondsen-Small Cap |
22,225 | * | 3,725 | 18,500 | * | |||||||||||||||
Maximus Managed Offshore, Ltd. |
21,340 | * | 21,340 | — | — | |||||||||||||||
Ret. Pl. For Union Carbide Corp. |
20,029 | * | 3,800 | 16,229 | * | |||||||||||||||
Maximus Capital Investments, Ltd. |
18,870 | * | 18,870 | — | — | |||||||||||||||
Westfiled Life Sciences Fund LP |
15,900 | * | 15,900 | — | — | |||||||||||||||
JPMP Global Healthtech Fund(3) |
15,500 | * | 15,500 | — | — | |||||||||||||||
JPMCB U.S. Small Company Equity II Growth |
15,475 | * | 2,650 | 12,825 | * | |||||||||||||||
Memorial Hospital of South Bend, Inc. |
12,500 | * | 11,500 | 1,000 | * | |||||||||||||||
PGH Pension |
11,600 | * | 10,700 | 900 | * | |||||||||||||||
DSM NV PENS VERZ MIJ-Small Cap |
11,025 | * | 1,825 | 9,200 | * | |||||||||||||||
JP Morgan Series Trust Small Company Growth
Portfolio |
10,825 | * | 2,125 | 8,700 | * | |||||||||||||||
Westfiled Life Sciences Fund LP II |
9,100 | * | 9,100 | — | — | |||||||||||||||
Nemours Foundation |
8,000 | * | 7,400 | 600 | * | |||||||||||||||
2
| Shares of Common Stock | Shares of Common Stock | |||||||||||||||||||
| Owned Prior to Offering | Owned After Offering | |||||||||||||||||||
| Percent of | Shares to be | Number of | Percent of | |||||||||||||||||
| Name of Selling Stockholder | Number of Shares | Class(%)(1) | Sold(2) | Shares(2) | Class(%)(2) | |||||||||||||||
Caddis Master Fund Ltd. |
6,934 | * | 6,934 | — | — | |||||||||||||||
JP Morgan Diversified Fund |
6,900 | * | 1,825 | 5,075 | * | |||||||||||||||
Maximus Managed Domestic, L.P. |
5,090 | * | 5,090 | — | — | |||||||||||||||
The Baetis Fund, LP |
4,799 | * | 4,335 | 464 | * | |||||||||||||||
Maximus Capital, L.P. |
4,700 | * | 4,700 | — | — | |||||||||||||||
EGS Private Healthcare Presidents Fund, L.P. |
3,508 | * | 3,508 | — | — | |||||||||||||||
Wilshire U.S. Equity Fund |
2,800 | * | 2,600 | 200 | * | |||||||||||||||
| * | Less than 1% | |
| (1) | Computed based on 42,312,412 shares of common stock outstanding as of March 28, 2002. | |
| (2) | Assumes all the shares of common stock that may be offered hereunder are sold. | |
| (3) | Registered in the name of Cudd & Co. | |
| (4) | 50,000 shares of common stock are held in the name of G. Nicholas Farwell and Gail M. Farwell JTWROS, and 25,000 shares of common stock are held in the name of G. Nicholas Farwell — Sep. Pty. |
The information regarding the selling stockholders may change from time to time. If required, we will describe these changes in one or more prospectus supplements.
The Date of This Prospectus Supplement Is May 7, 2002
3